PE20070141A1 - Derivados de isoquinolina como inhibidores de rho-cinasa - Google Patents
Derivados de isoquinolina como inhibidores de rho-cinasaInfo
- Publication number
- PE20070141A1 PE20070141A1 PE2006000735A PE2006000735A PE20070141A1 PE 20070141 A1 PE20070141 A1 PE 20070141A1 PE 2006000735 A PE2006000735 A PE 2006000735A PE 2006000735 A PE2006000735 A PE 2006000735A PE 20070141 A1 PE20070141 A1 PE 20070141A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- rho
- iloxi
- isoquinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C6), NH-ALQUIL(C1-C6), ENTRE OTROS; R2 ES H, HALOGENO O ALQUILO(C1-C6); R3 ES H, HALOGENO, OH, NH2, ENTRE OTROS; R4 ES H, HALOGENO, CN, ALQUILO(C1-C6), ENTRE OTROS; R5 ES H, HALOGENO, NO2, ALQUENILO(C2-C6), ENTRE OTROS; R6 ES H, ALQUILO(C1-C8), ALQUILENO(C1-C6)-C(O)NH2, ENTRE OTROS; R7 ES H, HALOGENO, ALQUENILO(C2-C6), CN, ENTRE OTROS; R8 ES H, HALOGENO O ALQUILO(C1-C6); L ES O U O-ALQUILENO(C1-C6); n ES DE 1 A 4. SON COMPUESTOS PREFERIDOS: ESTER TERC-BUTILICO DEL ACIDO 4-(5-BROMO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ESTER TERC-BUTILICO DEL ACIDO 4-(5-CIANO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ESTER TERC-BUTILICO DEL ACIDO 4-(5-AZIDO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE RHO-CINASA SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION PULMONAR, HIPERTENSION OCULAR, ANGINA DE PECHO, VASOESPASMO CEREBRAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05013868 | 2005-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070141A1 true PE20070141A1 (es) | 2007-02-21 |
Family
ID=35395794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000735A PE20070141A1 (es) | 2005-06-28 | 2006-06-26 | Derivados de isoquinolina como inhibidores de rho-cinasa |
Country Status (34)
Country | Link |
---|---|
US (2) | US8501736B2 (es) |
EP (1) | EP1899322B1 (es) |
JP (1) | JP5097701B2 (es) |
KR (1) | KR101327780B1 (es) |
CN (1) | CN101213187B (es) |
AR (1) | AR054518A1 (es) |
AT (1) | ATE441641T1 (es) |
AU (1) | AU2006264043B2 (es) |
BR (1) | BRPI0613597A2 (es) |
CA (1) | CA2611295C (es) |
CY (1) | CY1110108T1 (es) |
DE (1) | DE602006008945D1 (es) |
DK (1) | DK1899322T3 (es) |
DO (1) | DOP2006000149A (es) |
ES (1) | ES2331853T3 (es) |
GT (1) | GT200600273A (es) |
HK (1) | HK1122276A1 (es) |
HR (1) | HRP20090589T1 (es) |
IL (1) | IL188380A (es) |
MA (1) | MA29535B1 (es) |
MX (1) | MX2008000017A (es) |
MY (1) | MY146037A (es) |
NZ (1) | NZ565040A (es) |
PA (1) | PA8683501A1 (es) |
PE (1) | PE20070141A1 (es) |
PL (1) | PL1899322T3 (es) |
PT (1) | PT1899322E (es) |
RS (1) | RS51139B (es) |
RU (1) | RU2443688C2 (es) |
SI (1) | SI1899322T1 (es) |
TW (1) | TWI372756B (es) |
UY (1) | UY29641A1 (es) |
WO (1) | WO2007000240A1 (es) |
ZA (1) | ZA200710001B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535393A (ja) * | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
PT2125744E (pt) * | 2006-12-27 | 2011-07-01 | Sanofi Aventis | Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina |
BRPI0720909A2 (pt) | 2006-12-27 | 2016-11-01 | Sanofi Aventis | derivados de isoquinolina e isoquinolinona substituídos |
BRPI0720862A2 (pt) | 2006-12-27 | 2014-02-25 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase |
JP5405316B2 (ja) * | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノリン誘導体 |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2303845B1 (en) * | 2008-06-24 | 2013-09-18 | Sanofi | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
CN102131785B (zh) * | 2008-06-24 | 2014-10-29 | 赛诺菲-安万特 | 6-取代的异喹啉和异喹啉酮 |
JP5713893B2 (ja) * | 2008-06-24 | 2015-05-07 | サノフイ | Rho−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類 |
GB0812969D0 (en) * | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
US8299055B2 (en) | 2008-10-02 | 2012-10-30 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and the use thereof |
EP2177218A1 (en) | 2008-10-15 | 2010-04-21 | Medizinische Universität Wien | Regenerative therapy |
JP5391372B2 (ja) * | 2009-07-08 | 2014-01-15 | 公益財団法人名古屋産業科学研究所 | 芳香族アミン化合物の製造方法 |
EP2552893B1 (en) * | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Antibacterial isoquinolin-3-ylurea derivatives |
KR20130129244A (ko) | 2010-12-17 | 2013-11-27 | 에프. 호프만-라 로슈 아게 | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
CA2849566C (en) | 2011-11-09 | 2021-02-09 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
EP2855448B1 (en) | 2012-05-15 | 2017-02-08 | Cancer Research Technology Ltd | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
JP6461150B2 (ja) | 2013-07-31 | 2019-01-30 | ノバルティス アーゲー | 1,4−二置換ピリダジン誘導体およびsmn欠損に関連する状態を処置するためのその使用 |
FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
NZ733135A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
PE20200008A1 (es) | 2017-03-30 | 2020-01-06 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
JP2021527125A (ja) * | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドDisarm Therapeutics, Inc. | Sarm1阻害剤 |
JP7386841B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
CN110407777B (zh) * | 2019-08-15 | 2022-09-09 | 湖北远大富驰医药化工股份有限公司 | 一种呋虫胺的合成方法 |
CN111574413B (zh) * | 2020-06-08 | 2022-04-05 | 杭州尚合生物医药科技有限公司 | 一种2-氨甲基吡啶与dmf-dma作为胺源的磺酰脒的制备方法 |
CN113372341A (zh) * | 2021-07-02 | 2021-09-10 | 黄淮学院 | 三氟醋酸二氢异喹啉衍生物的合成方法及装置 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
WO1992002476A1 (en) | 1990-07-31 | 1992-02-20 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
NZ334613A (en) * | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
EP1007525A1 (en) | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
HUP0204496A3 (en) * | 2000-01-20 | 2004-07-28 | Eisai Co Ltd | Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
DE60211317T2 (de) | 2001-03-23 | 2007-04-12 | Bayer Corp. | Rho-kinase inhibitoren |
EP1389194A2 (en) | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
WO2004009555A1 (ja) * | 2002-07-22 | 2004-01-29 | Asahi Kasei Pharma Corporation | 5−置換イソキノリン誘導体 |
CN100383140C (zh) | 2002-09-12 | 2008-04-23 | 麒麟麦酒株式会社 | 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂 |
WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
AU2004275720B2 (en) | 2003-09-23 | 2008-04-24 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
JP4718467B2 (ja) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
EP1671962A1 (en) * | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
JP2005232175A (ja) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | 5−置換イソキノリン医薬 |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
MX2008000956A (es) | 2005-07-26 | 2008-03-27 | Sanofi Aventis | Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa. |
PT1910333E (pt) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
JP4033221B2 (ja) | 2005-12-02 | 2008-01-16 | ダイキン工業株式会社 | 冷媒加熱装置 |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7618985B2 (en) * | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
PT2102164E (pt) | 2006-12-27 | 2011-01-21 | Sanofi Aventis | Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina |
BRPI0720909A2 (pt) | 2006-12-27 | 2016-11-01 | Sanofi Aventis | derivados de isoquinolina e isoquinolinona substituídos |
-
2006
- 2006-06-13 MX MX2008000017A patent/MX2008000017A/es active IP Right Grant
- 2006-06-13 BR BRPI0613597-8A patent/BRPI0613597A2/pt not_active IP Right Cessation
- 2006-06-13 WO PCT/EP2006/005648 patent/WO2007000240A1/en active Application Filing
- 2006-06-13 ES ES06754323T patent/ES2331853T3/es active Active
- 2006-06-13 CA CA2611295A patent/CA2611295C/en not_active Expired - Fee Related
- 2006-06-13 NZ NZ565040A patent/NZ565040A/en not_active IP Right Cessation
- 2006-06-13 EP EP06754323A patent/EP1899322B1/en active Active
- 2006-06-13 CN CN2006800238102A patent/CN101213187B/zh not_active Expired - Fee Related
- 2006-06-13 PL PL06754323T patent/PL1899322T3/pl unknown
- 2006-06-13 PT PT06754323T patent/PT1899322E/pt unknown
- 2006-06-13 RS RSP-2009/0516A patent/RS51139B/sr unknown
- 2006-06-13 AT AT06754323T patent/ATE441641T1/de active
- 2006-06-13 DE DE602006008945T patent/DE602006008945D1/de active Active
- 2006-06-13 KR KR1020077030517A patent/KR101327780B1/ko not_active IP Right Cessation
- 2006-06-13 AU AU2006264043A patent/AU2006264043B2/en not_active Ceased
- 2006-06-13 SI SI200630484T patent/SI1899322T1/sl unknown
- 2006-06-13 RU RU2008102968/04A patent/RU2443688C2/ru not_active IP Right Cessation
- 2006-06-13 JP JP2008518659A patent/JP5097701B2/ja not_active Expired - Fee Related
- 2006-06-13 DK DK06754323T patent/DK1899322T3/da active
- 2006-06-26 DO DO2006000149A patent/DOP2006000149A/es unknown
- 2006-06-26 TW TW095122877A patent/TWI372756B/zh not_active IP Right Cessation
- 2006-06-26 GT GT200600273A patent/GT200600273A/es unknown
- 2006-06-26 AR ARP060102738A patent/AR054518A1/es unknown
- 2006-06-26 PE PE2006000735A patent/PE20070141A1/es not_active Application Discontinuation
- 2006-06-27 MY MYPI20063032A patent/MY146037A/en unknown
- 2006-06-27 PA PA20068683501A patent/PA8683501A1/es unknown
- 2006-06-29 UY UY29641A patent/UY29641A1/es unknown
-
2007
- 2007-11-20 ZA ZA200710001A patent/ZA200710001B/xx unknown
- 2007-12-07 MA MA30457A patent/MA29535B1/fr unknown
- 2007-12-20 US US11/961,193 patent/US8501736B2/en not_active Expired - Fee Related
- 2007-12-24 IL IL188380A patent/IL188380A/en not_active IP Right Cessation
-
2008
- 2008-12-12 HK HK08113534.8A patent/HK1122276A1/xx not_active IP Right Cessation
-
2009
- 2009-11-03 HR HR20090589T patent/HRP20090589T1/hr unknown
- 2009-11-25 CY CY20091101226T patent/CY1110108T1/el unknown
-
2011
- 2011-06-15 US US13/160,983 patent/US8722671B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070141A1 (es) | Derivados de isoquinolina como inhibidores de rho-cinasa | |
PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
PE20061439A1 (es) | DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR) | |
PE20071061A1 (es) | Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
PE20120024A1 (es) | DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN | |
PE20080552A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
PE20091834A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona tiofenilo-sustituida como inhibidores de bace-1 y composiciones que los contienen | |
PE20090546A1 (es) | Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5 | |
PE20090326A1 (es) | Compuestos heterociclos como inhibidores de erk | |
PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |